Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,482 Mln
Revenue (TTM)
$-- Mln
Net Profit (TTM)
$-- Mln
ROE
-2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
65
Industry P/E
--
EV/EBITDA
-2.4
Div. Yield
0 %
Debt to Equity
-0.8
Book Value
$--
EPS
$-1.4
Face value
--
Shares outstanding
48,472,410
CFO
€-238.85 Mln
EBITDA
€-293.05 Mln
Net Profit
€-332.76 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
| 47.4 | 9.8 | 47.4 | 851.7 | 113.0 | 17.8 | -- |
|
BSE Sensex*
| -13.7 | -10.1 | -14.2 | -3.8 | 7.4 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
| 705.6 | -60.3 | 98.4 | -54.7 | -50.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
|
34.1 | 1,482.3 | -11.6 | -68.1 | -- | 201.7 | -- | 65.0 |
| 22.3 | 12,800.6 | 19,628.0 | 978.0 | 9.1 | 6.8 | 11.4 | 0.8 | |
| 29.8 | 1,904.4 | 1,112.2 | 320.9 | -17.8 | 10.5 | 5.2 | 0.5 | |
| 6.0 | 244.4 | 67.0 | 1.5 | 37.3 | 2.2 | -- | 4.9 | |
| 1.4 | 121.0 | 2.7 | -47.2 | -86.4 | 734.6 | -- | 20.1 | |
| 5.4 | 557.3 | 9.2 | -184.2 | -518.6 | 265.7 | -- | 2.1 | |
| 6.3 | 913.1 | 174.7 | -115.2 | 0.0 | -80.2 | -- | 7.4 |
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline... hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France. Address: 60 rue de Wattignies, Paris, France, 75012 Read more
Co-Founder, President of the Executive Board & CEO
Mr. Laurent Levy Ph.D.
Co-Founder, President of the Executive Board & CEO
Mr. Laurent Levy Ph.D.
Headquarters
Paris
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Nanobiotix (NBTX) is $34.07 (NASDAQ) as of 01-Apr-2026 16:00 EDT. Nanobiotix (NBTX) has given a return of 113.01% in the last 3 years.
Since, TTM earnings of Nanobiotix (NBTX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-1.99
|
-2.06
|
|
2023
|
-7.12
|
-153.26
|
|
2022
|
-2.24
|
-4.73
|
|
2021
|
-6.00
|
10.52
|
|
2020
|
-16.89
|
8.06
|
The 52-week high and low of Nanobiotix (NBTX) are Rs 41.89 and Rs 2.99 as of 02-Apr-2026.
Nanobiotix (NBTX) has a market capitalisation of $ 1,482 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Nanobiotix (NBTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$3.20
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.